Genetic polymorphisms of GSTP1 and XRCC1: prediction of clinical outcome of platinum-based chemotherapy in advanced non-small cell lung cancer (NSCLC) patients
PRINCIPLES: Platinum agents cause DNA cross-linking and oxidative damage. Genetic polymorphisms of GSTP1 and XRCC1 involved in glutathione metabolic and DNA repair pathways may explain inter individual differences in chemosensitivity and clinical outcome in NSCLC patients treated with platinum-...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SMW supporting association (Trägerverein Swiss Medical Weekly SMW)
2011-10-01
|
| Series: | Swiss Medical Weekly |
| Subjects: | |
| Online Access: | https://www.smw.ch/index.php/smw/article/view/1367 |
| _version_ | 1811194120745517056 |
|---|---|
| author | F zhou Z yu T jiang H lv R yao J liang |
| author_facet | F zhou Z yu T jiang H lv R yao J liang |
| author_sort | F zhou |
| collection | DOAJ |
| description |
PRINCIPLES: Platinum agents cause DNA cross-linking and oxidative damage. Genetic polymorphisms of GSTP1 and XRCC1 involved in glutathione metabolic and DNA repair pathways may explain inter individual differences in chemosensitivity and clinical outcome in NSCLC patients treated with platinum-based regimens.
METHODS: We used DNA sequencing methods to evaluate genetic polymorphisms of the GSTP1A313G and XRCC1G28152A in 111 patients with stage IV NSCLC treated with platinum-based chemotherapy. Clinical response was evaluated according to RECIST criteria after 2–3 cycles of chemotherapy and time to progression (TTP) was calculated from the time of initial treatment to disease progression.
RESULTS: GSTP1A313G and XRCC1G28152A polymorphisms, both alone and in combination, were significantly associated with response to treatment and clinical outcome (p<0.05) in NSCLC patients treated with platinum-based chemotherapy. These polymorphisms independently predicted clinical outcome even after taking into account age, gender, tumour histology, tumour differentiation and chemotherapy regimens.
CONCLUSION: Genetic polymorphisms of GSTP1 and XRCC1 may be important predictive factors in platinum-treated patients with advanced NSCLC. Assessment of genetic variations of GSTP1 and XRCC1 could facilitate therapeutic decisions for individualised therapy in advanced NSCLC.
|
| first_indexed | 2024-04-12T00:20:39Z |
| format | Article |
| id | doaj.art-d1d491636a024b328c1dbc85febe5b36 |
| institution | Directory Open Access Journal |
| issn | 1424-3997 |
| language | English |
| last_indexed | 2024-04-12T00:20:39Z |
| publishDate | 2011-10-01 |
| publisher | SMW supporting association (Trägerverein Swiss Medical Weekly SMW) |
| record_format | Article |
| series | Swiss Medical Weekly |
| spelling | doaj.art-d1d491636a024b328c1dbc85febe5b362022-12-22T03:55:44ZengSMW supporting association (Trägerverein Swiss Medical Weekly SMW)Swiss Medical Weekly1424-39972011-10-01141414210.4414/smw.2011.13275Genetic polymorphisms of GSTP1 and XRCC1: prediction of clinical outcome of platinum-based chemotherapy in advanced non-small cell lung cancer (NSCLC) patientsF zhouZ yuT jiangH lvR yaoJ liang PRINCIPLES: Platinum agents cause DNA cross-linking and oxidative damage. Genetic polymorphisms of GSTP1 and XRCC1 involved in glutathione metabolic and DNA repair pathways may explain inter individual differences in chemosensitivity and clinical outcome in NSCLC patients treated with platinum-based regimens. METHODS: We used DNA sequencing methods to evaluate genetic polymorphisms of the GSTP1A313G and XRCC1G28152A in 111 patients with stage IV NSCLC treated with platinum-based chemotherapy. Clinical response was evaluated according to RECIST criteria after 2–3 cycles of chemotherapy and time to progression (TTP) was calculated from the time of initial treatment to disease progression. RESULTS: GSTP1A313G and XRCC1G28152A polymorphisms, both alone and in combination, were significantly associated with response to treatment and clinical outcome (p<0.05) in NSCLC patients treated with platinum-based chemotherapy. These polymorphisms independently predicted clinical outcome even after taking into account age, gender, tumour histology, tumour differentiation and chemotherapy regimens. CONCLUSION: Genetic polymorphisms of GSTP1 and XRCC1 may be important predictive factors in platinum-treated patients with advanced NSCLC. Assessment of genetic variations of GSTP1 and XRCC1 could facilitate therapeutic decisions for individualised therapy in advanced NSCLC. https://www.smw.ch/index.php/smw/article/view/1367carcinomagenetic polymorphismsglutathione S-transferase pinon-small-cell lungplatinumX-ray repair cross complementing protein 1 |
| spellingShingle | F zhou Z yu T jiang H lv R yao J liang Genetic polymorphisms of GSTP1 and XRCC1: prediction of clinical outcome of platinum-based chemotherapy in advanced non-small cell lung cancer (NSCLC) patients Swiss Medical Weekly carcinoma genetic polymorphisms glutathione S-transferase pi non-small-cell lung platinum X-ray repair cross complementing protein 1 |
| title | Genetic polymorphisms of GSTP1 and XRCC1: prediction of clinical outcome of platinum-based chemotherapy in advanced non-small cell lung cancer (NSCLC) patients |
| title_full | Genetic polymorphisms of GSTP1 and XRCC1: prediction of clinical outcome of platinum-based chemotherapy in advanced non-small cell lung cancer (NSCLC) patients |
| title_fullStr | Genetic polymorphisms of GSTP1 and XRCC1: prediction of clinical outcome of platinum-based chemotherapy in advanced non-small cell lung cancer (NSCLC) patients |
| title_full_unstemmed | Genetic polymorphisms of GSTP1 and XRCC1: prediction of clinical outcome of platinum-based chemotherapy in advanced non-small cell lung cancer (NSCLC) patients |
| title_short | Genetic polymorphisms of GSTP1 and XRCC1: prediction of clinical outcome of platinum-based chemotherapy in advanced non-small cell lung cancer (NSCLC) patients |
| title_sort | genetic polymorphisms of gstp1 and xrcc1 prediction of clinical outcome of platinum based chemotherapy in advanced non small cell lung cancer nsclc patients |
| topic | carcinoma genetic polymorphisms glutathione S-transferase pi non-small-cell lung platinum X-ray repair cross complementing protein 1 |
| url | https://www.smw.ch/index.php/smw/article/view/1367 |
| work_keys_str_mv | AT fzhou geneticpolymorphismsofgstp1andxrcc1predictionofclinicaloutcomeofplatinumbasedchemotherapyinadvancednonsmallcelllungcancernsclcpatients AT zyu geneticpolymorphismsofgstp1andxrcc1predictionofclinicaloutcomeofplatinumbasedchemotherapyinadvancednonsmallcelllungcancernsclcpatients AT tjiang geneticpolymorphismsofgstp1andxrcc1predictionofclinicaloutcomeofplatinumbasedchemotherapyinadvancednonsmallcelllungcancernsclcpatients AT hlv geneticpolymorphismsofgstp1andxrcc1predictionofclinicaloutcomeofplatinumbasedchemotherapyinadvancednonsmallcelllungcancernsclcpatients AT ryao geneticpolymorphismsofgstp1andxrcc1predictionofclinicaloutcomeofplatinumbasedchemotherapyinadvancednonsmallcelllungcancernsclcpatients AT jliang geneticpolymorphismsofgstp1andxrcc1predictionofclinicaloutcomeofplatinumbasedchemotherapyinadvancednonsmallcelllungcancernsclcpatients |